In vitro comparative evaluation under static conditions of the hemocompatibility of four types of tubing for cardiopulmonary bypass

Biomaterials

Volumn 20, Issue 17, 1999, Pages 1561-1571

  Harmand, M F ^a,b   Briquet, F ^b  

^a INSERM   (France)

^b LEMI   (France)

Author keywords

Complement; Cytotoxicity; Hemocompatibility; Hemolysis; Silicone tubing and PVC tubing

Indexed keywords

BIOCOMPATIBILITY; BIOMARKERS; BLOOD; CARDIOVASCULAR SURGERY; COAGULATION; CYTOLOGY; POLYVINYL CHLORIDES; SILICONES; TOXICITY; TUBING;

CYTOTOXICITY; HEMOCOMPATIBILITY; HEMOLYSIS;

BIOMATERIALS;

BIOMATERIAL; BLOOD CLOTTING FACTOR; COMPLEMENT; HEPARIN; PLATINUM; POLYVINYLCHLORIDE; SILICONE;

ARTICLE; BLOOD; BLOOD COMPATIBILITY; CARDIOPULMONARY BYPASS; CELL ACTIVATION; COMPARATIVE STUDY; COMPLEMENT SYSTEM; CYTOTOXICITY; FIBRINOLYSIS; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LEUKOCYTE ADHERENCE; PRIORITY JOURNAL; SERUM; THROMBOSIS; TUBE;

BIOCOMPATIBLE MATERIALS; BLOOD; BLOOD COAGULATION; CARDIOPULMONARY BYPASS; CELL ADHESION; CELL MEMBRANE; COMPLEMENT ACTIVATION; EVALUATION STUDIES; FLOW CYTOMETRY; HEMOLYSIS; HEPARIN; HUMANS; PLATINUM; POLYVINYL CHLORIDE; SILICONE ELASTOMERS; THROMBOSIS;

EID: 0033198074     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0142-9612(99)00051-4     Document Type: Article

References (34)

1. [1] Klinkmann H. Role of biomaterials in application of artificial organs. In: Courtney J, Gilchrist T, editors. Biomaterials in artificial organs. London: MacMillan, 1984. p. 1-8.
2. [2] Colton CK, Ward RA, Shaldon S. Scientific basis for assessment of biocompatibility in extracorporeal blood treatment. Nephrol Dial Transplant 1994;9:11-7.
3. [3] Courtney JM, Lamba NMK, Sundaram M, Forbes CD. Biomaterials for blood-contacting applications. Biomaterials 1994;10:737-44.
4. [4] Williams DF. Biocompatibility: an overview. In: Williams D, editor. Concise encyclopedia of medical and dental materials. Oxford: Pergamon Press, 1990. p. 51-9.
5. [5] Kirklin JK, George JF, Holman W. The inflammatory response to cardiopulmonary bypass. In: Gravlee GP, Davis RF, Utley JR, editors. Cardiopulmonary bypass: principles and practices. Baltimore: Williams Wilkins, 1993. p. 233-48.
6. [6] Kirklin JK, Westaby S, Blackstone EH, Kirklin JW, Chenoweth DE, Pacifico AD. Complement and the damaging effects of cardiopulmonary bypass. J Thorac Cardiovasc Surg 1983;86:845-57.
7. [7] Utley JR. The inflammatory response to cardiopulmonary bypass. In: Gravlee GP, Davis RF, Utley JR, editors. Cardiopulmonary bypass: principles and practices. Baltimore: Williams Wilkins, 1993. p. 249-66.
8. [8] Wright G. Blood cell trauma. In: Gravlee GP, Davis RF, Utley JR, editors. Cardiopulmonary bypass: principles and practices. Baltimore: Williams Wilkins, 1993. p. 269-76.
9. [9] Komer C. Physiologic changes of cardiopulmonary bypass. In: Casthely PA, Bregman D, editors. Cardiopulmonary bypass: physiology, related complications and pharmacology. Mount Kisko: Futura Publishing, 1991. p. 37-84.
10. [10] Sundaram S, Courtney JM, Taggart DP, et al. Biocompatibility of cardiopulmonary bypass: influence on blood compatibility of device type, mode of blood flow and duration of application. Int J Artif Org 1994;17:118-26.
11. [11] Janvier G, Baquey C, Roth C, Benillan N, Bélisle S, Hardy JF. Extracorporeal circulation, hemocompatibility and biomaterials. Ann Thorac Surg 1996;62:1926-34.
12. [12] Rhodes NP, Kumary TV, Williams DF. Influence of wall shear rate on parameters of blood compatibility of intravascular catheters. Biomaterials 1996;17:1995-2002.
13. [13] Isetta C. Tuyaux en silicone au cours de la Circulation Extra-Corporelle, intérêts comparés au PVC. Technocoeur 1993; 12:187-91.
14. [14] ISO 10993-4. Biological evaluation of medical devices - Part 4: Selection of tests for interactions with blood, 1992.
15. [15] Noll W. Chemistry and technology of silicones. eds. Academic Press Limited, London: Harcourt Brace Jovanovitch, 1968.
16. [16] ISO 10993-5. Biological evaluation of medical devices - Part 5: Tests for cytotoxicity: in vitro methods, 1992.
17. [17] ASTM F756-87. Practice for assessment of the hemolytic properties of materials, 1992.
18. [18] ISO 10993-12. Biological evaluation of medical devices - Part 12: Sample preparation and reference materials, 1992.
19. [19] Ito Y, Sisido M, Imanishi Y. Synthesis and antithrombogenicity of anionic polyurethanes and heparin-bound polyurethanes. J Biomed Mater Res 1986;20:1157-77.
20. [20] Mayer MM. Complement and complement fixation. In: Kabat EA, Mayer MM, editors. Experimental immunochemistry, 2nd ed. Illinois: Thomas Springfield, 1961. p. 133-56.
21. [21] Bruil A. In vitro leukocyte adhesion to modified polyurethane surfaces - Effect of wettability. J Colloid Interface Sci 1994; 165:72-81.
22. [22] Missirlis YF. In: Missirlis YF, Wautier J-L, editors. The role of platelets in blood-biomaterial interactions. Dordrecht: Kluwer Academic Publishers, 1993. p. 15-32.
23. [23] Holmsen H. The blood platelet release reaction. Scand J Haematol 1969;8:1-26.
24. [24] Kazatchkine MD, Carreno MP. Activation of the complement system at the interface between blood and artificial surfaces. Biomaterials 1988;9:30-5.
25. [25] Videm V. Complement activation induced by different tubings used for cardiopulmonary bypass. Extra-Corporeal Technol 1989;21:29-33.
26. [26] Kuroki K, Roy S, Laerum F, Mollnes TE, Solheim BG, Videm V Complement activation by angiographic catheters in vitro. J Vascular Interventional Radiol 1995;6:819-26.
27. [27] Toufik J, Labarre D. Reduction of complement activation by DEAE on polysaccharide surfaces. Biomaterials 1995;16:1080-6.
28. [28] Darquy S, Pueyo M, Capron F, Reach G. Complement activation by alginate-polylysine microcapsules used for islet transplantation. Artif Organs 1994;18:898-903.
29. [29] Pekna M, Hagman L, Halden E, Nilsson R, Nilsson B, Thelin S. Complement activation during cardiopulmonary bypass: effects of immobilized heparin. Ann Thorac Surg 1994;58:421-4.
30. [30] Mollnes TE, Riesenfeld J, Garred P, Nordström E, Hogasen K, Fosse E, Götze O, Harboe M. A new model for evaluation of biocompatibility: combined determination of neoepitopes in blood and on artificial surfaces demonstrates reduced complement activation by immobilization of heparin. Artif Organs 1995;19: 909-17.
31. [31] Sundaram S, Lim F, Cooper SL, Colman RW. Role of leucocytes in coagulation induced by artificial surfaces: investigation of expression of Mac-1, granulocyte elastase release and leucocyte adhesion on modified polyurethanes. Biomaterials 1996;17:1041-7.
32. [32] Yung LYL, Lim F, Khan MMH et al. Neutrophil adhesion on surfaces preadsorbed with high molecular weight kininogen under well-defined flow conditions. Immunopharmacol 1996;32:19-23.
33. [33] Jones DA, Smith CW, McIntire LV. Leucocyte adhesion under flow conditions: principles important in tissue engineering. Biomaterials 1996;17:337-47.
34. [34] Von Appen K, Goolsby C, Mehl P, Goewert R, Ivanovich P. Leukocyte adhesion molecules as biocompatibility markers for hemodialysis membranes. ASAIO 1994;40:609-15.